Evofem Biosciences Announces Peer-Reviewed Publication of the Pivotal Phase 3 AMPOWER Study Results For Phexxi™ (lactic acid, citric acid and potassium bitartrate) in Contraception

• NASDAQ: $EVFM
• Notified: $3.07
• 08:31 EDT